SIONSionna Therapeutics, Inc.

$51.04+193% 1Y

$51.04

$4.5052 weeks$51.04

SION in its own filings

Nothing in SION's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

Events found in the filings · across 231 filings · the record starts in 2024

Hard flags: none
Hard flags
Most recent filing: Sep 14, 2026
Most recent filing · Form 8-K
Record starts: Oct 10, 2024
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 4, 2026
SEC comment-letter activity6 occurrences: 2025-02-04

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 14, 2026On September 9, 2026, the Board of Directors (the “Board”) of Sionna Therapeutics, Inc. (the “Company”) approved a restructuring plan (the “Restructuring”) intended to focus its resources on advancing the Company’s SION-451 and SION-2222 dual combination program and extend the Company’s cash runway.Exit or disposal costs (restructuring) · Form 8-K
Aug 10, 2026On August 10, 2026, Sionna Therapeutics, Inc., or the Company, announced topline data from both its PreciSION CF Phase 2a proof-of-concept trial of SION-719 when added to current standard of care and its Phase 1 trial of SION-451-based proprietary dual combinations in healthy subjects.Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

opening the record…